X-Linked Severe Combined Immunodeficiency
Symptoms, Doctors, Treatments, Advances & More

X-Linked Severe Combined Immunodeficiency Overview

Save information for later
Sign Up

Learn About X-Linked Severe Combined Immunodeficiency

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top X-Linked Severe Combined Immunodeficiency Local Doctors?
Elite in X-Linked Severe Combined Immunodeficiency
Pediatric Allergy and Immunology
Elite in X-Linked Severe Combined Immunodeficiency
Pediatric Allergy and Immunology

The Center For Allergy, Asthma & Immune Disorders

360 Essex Street, Suite 302, 
Hackensack, NJ 
Languages Spoken:
English, Spanish

Juan Aumaitre is a Pediatric Allergy and Immunologist practicing medicine in Hackensack, New Jersey. Dr. Aumaitre is rated as an Elite provider by MediFind in the treatment of X-Linked Severe Combined Immunodeficiency. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses X-Linked Severe Combined Immunodeficiency, Severe Combined Immunodeficiency (SCID), Primary Immunodeficiency (PID), and Allergic Rhinitis. Dr. Aumaitre is board certified in American Board Of Allergy And Immunology and American Board Of Internal Medicine.

Elite in X-Linked Severe Combined Immunodeficiency
Elite in X-Linked Severe Combined Immunodeficiency

Boston Children's Hospital

300 Longwood Ave, 
Boston, MA 
Languages Spoken:
English

Luigi Notarangelo is a Pediatrics provider practicing medicine in Boston, Massachusetts. Dr. Notarangelo is rated as an Elite provider by MediFind in the treatment of X-Linked Severe Combined Immunodeficiency. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Severe Combined Immunodeficiency (SCID), X-Linked Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Immunodeficiency with Hyper IgM Type 1, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in X-Linked Severe Combined Immunodeficiency
Hematology | Oncology
Elite in X-Linked Severe Combined Immunodeficiency
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
Languages Spoken:
English

Ewelina Mamcarz is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Mamcarz is rated as an Elite provider by MediFind in the treatment of X-Linked Severe Combined Immunodeficiency. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses X-Linked Severe Combined Immunodeficiency, Severe Combined Immunodeficiency (SCID), Graft Versus Host Disease (GvHD), Leukemia, and Bone Marrow Transplant.

What are the Latest Advances for X-Linked Severe Combined Immunodeficiency?
What are the latest X-Linked Severe Combined Immunodeficiency Clinical Trials?
Screening and Baseline Assessment of Patients With Abnormalities of Immune Function

Summary: This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation. This may include inherited conditions, such as X-linked severe combined immunodeficiency (XSCID), chronic granulomatous disease (CGD), and leukocyte adhesion deficiency (LAD), or conditions resulting from outside factors, such as graft-versus-host disease (GVHD)....

Match to trials
Find the right clinical trials for you in under a minute
Get started
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Summary: This is a Phase I/II non-randomized clinical trial of ex vivo hematopoietic stem cell (HSC) gene transfer treatment for X-linked severe combined immunodeficiency (XSCID, also known as SCID-X1) using a self-inactivating lentiviral vector incorporating additional features to improve safety and performance. The study will treat 35 patients with XSCID who are between 2 and 50 years of age and who have...